梅克尔细胞癌与免疫逃逸:梅克尔细胞多瘤病毒小T抗原诱导的表面改变可通过治疗干预逆转
梅克尔细胞多瘤病毒是多数梅克尔细胞癌(MCC)的病因,病毒阳性MCC突变率低且肿瘤细胞增殖依赖病毒癌蛋白小T抗原(sT)和大T抗原。本研究探讨sT促进转移的机制,发现sT通过改变多种MCC表面分子影响选择素配体结合与加工及肿瘤细胞免疫识别,并调控抑制巨噬细胞吞噬的表面抗原CD47。应用sT短发夹RNA、靶向CD47的小干扰RNA或治疗性抗CD47抗体可恢复MCC细胞的免疫识别,提示CD47是MCC的有前景治疗靶点,阻断CD47-SIRPα相互作用可促进MCC细胞吞噬,并可能与PD-1/PD-L1轴联合用于MCC治疗。
要点
- sT通过改变MCC表面分子影响选择素配体结合与加工及免疫识别。
- sT调控表面抗原CD47,从而抑制巨噬细胞对肿瘤细胞的吞噬。
- 阻断CD47-SIRPα或使用抗CD47抗体可恢复MCC细胞免疫识别与吞噬。
核心结论
- CD47是MCC细胞上有前景的治疗靶点,阻断CD47-SIRPα相互作用可有效促进MCC细胞吞噬,并可能与PD-1/PD-L1轴联合作为有前景的MCC免疫治疗策略。
研究设计与样本
- 本研究为实验研究,探讨梅克尔细胞多瘤病毒癌蛋白尤其是sT促进转移的可能机制。
主要发现
- sT特异性影响选择素配体结合与加工,通过改变多种MCC表面分子的呈递影响初始转移事件和肿瘤细胞免疫识别。
- sT调控抑制巨噬细胞吞噬的表面抗原CD47。
- 应用sT短发夹RNA、靶向CD47的小干扰RNA或治疗性抗CD47抗体,可恢复MCC细胞的免疫识别。
临床怎么用
- 作者认为,CD47是MCC细胞上有前景的治疗靶点,阻断CD47-SIRPα相互作用可有效促进MCC细胞吞噬,并可能与PD-1/PD-L1轴联合用于MCC治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Merkel cell polyomavirus is the causative agent for most Merkel cell carcinomas (MCCs). This highly aggressive skin cancer shows rapid progression, with metastasis being a significant challenge for patient therapy. Virus-positive MCCs show low mutation rates, and tumor cell proliferation is dependent on viral oncoproteins small T antigen (sT) and large T antigen. Although the role of sT and large T antigen in early events of tumorigenesis has been extensively studied, their role in tumor progression has been scarcely addressed. In this study, we investigate the possible mechanisms of how Merkel cell polyomavirus oncoproteins, particularly sTs, contribute to metastasis. We show that sT specifically affects selectin ligand binding and processing by altering the presentation of multiple MCC surface molecules, thereby influencing initial metastasis events and tumor cell immune recognition. Furthermore, we show that sT regulates the surface antigen CD47, which inhibits phagocytosis by macrophages. By applying either sT short hairpin RNAs, CD47-targeted small interfering RNAs, or a therapeutic anti-CD47 antibody, we show that immune recognition of MCC cells can be restored. Thus, CD47 is a promising therapeutic target on MCC cells. Blocking the CD47‒SIRPα interaction effectively promotes phagocytosis of MCC cells and might be a promising combinatorial immunotherapy approach together with PD-1/PD-L1 axis in MCC treatment.
引用
- Schlemeyer T, Ohnezeit D, Virdi S, et al. Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention. J Invest Dermatol. 2022. PMID: 35636504. doi:10.1016/j.jid.2022.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。